Karyopharm Therapeutics adds US104m to market cap in the past 7 days, though investors from three years ago are still down 90
KPTI Stock | USD 0.85 0.07 8.97% |
Under 59% of all Karyopharm Therapeutics' traders are looking to take a long position. The analysis of the overall investor sentiment regarding Karyopharm Therapeutics suggests that some traders are interested. Karyopharm Therapeutics' investing sentiment shows overall attitude of investors towards Karyopharm Therapeutics.
Karyopharm |
It is a pleasure to report that the Karyopharm Therapeutics Inc. is up 1 percent in the last quarter. But...
Read at finance.yahoo.com
Karyopharm Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Karyopharm Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Karyopharm Therapeutics Fundamental Analysis
We analyze Karyopharm Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karyopharm Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karyopharm Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Karyopharm Therapeutics is currently under evaluation in target price category among its peers.
Karyopharm Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Karyopharm Therapeutics stock to make a market-neutral strategy. Peer analysis of Karyopharm Therapeutics could also be used in its relative valuation, which is a method of valuing Karyopharm Therapeutics by comparing valuation metrics with similar companies.
Peers
Karyopharm Therapeutics Related Equities
REPL | Replimune | 35.11 | ||||
BLUE | Bluebird Bio | 16.67 | ||||
GOSS | Gossamer Bio | 6.06 | ||||
LYRA | Lyra Therapeutics | 5.56 | ||||
NVCT | Nuvectis Pharma | 4.08 | ||||
GBIO | Generation Bio | 3.79 | ||||
NUVB | Nuvation Bio | 3.70 | ||||
KRON | Kronos Bio | 3.45 | ||||
RLYB | Rallybio Corp | 3.03 | ||||
MRSN | Mersana Therapeutics | 3.03 | ||||
ABOS | Acumen Pharmaceuticals | 2.60 | ||||
PMVP | Pmv Pharmaceuticals | 2.55 | ||||
CTMX | CytomX Therapeutics | 2.30 | ||||
ASMB | Assembly Biosciences | 2.17 | ||||
GLUE | Monte Rosa | 1.68 | ||||
MREO | Mereo BioPharma | 1.09 | ||||
AGIO | Agios Pharm | 0.25 | ||||
HOOK | Hookipa Pharma | 6.52 | ||||
XFOR | X4 Pharmaceuticals | 8.11 |
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |